Stapleford-Athens 2011 International Addiction Conference Further Experience with Ambulatory Benzodiazepine detox Dr George O’Neil

Slides:



Advertisements
Similar presentations
Prescription Drugs. What is prescription drug abuse? Taking a prescription drug that is not prescribed for you, or taking it for reasons or in dosages.
Advertisements

Best Practice Tom Shiffler, MD 7/23/10
Benzodiazepines and risk behaviour Graham Mackintosh Critical Incidents Training Officer Scottish Drugs Forum.
Alcohol Antagonists 1. What is an alcohol antagonist? An alcohol antagonist is a drug that specifically blocks the effects of alcohol. If you take an.
Medication Assisted Treatment: An Introduction Deborah A. Orr, Ph.D., RN Remington College School of Nursing.
Drug Addiction. History: Opiate Effects Characteristics of drug addiction: Characteristics of drug addiction: Tolerance: decreased drug effect w/ repeated.
Investigating a Novel Neutral Antagonist, 6Beta-Naltrexol, in Alleviating Cocaine Withdrawal Symptoms Timothy DeYoung, Michelle Mueller, and Dr. Boyette-Davis.
University Hospital “Sisters of Charity” Psychiatric Clinic Vinogradska c. 29, 1000 Zagreb, Croatia Davor Moravek Addiction and psychotic.
Lesson 18. Learning Objectives  To understand biological methods of stress management. Success Criteria 1. Produce evaluation notes about the use of.
Biological methods of stress management Stress Biological Psychology.
Biological Methods of Stress Management. Definition Stress management is the attempt to cope with negative effects of stress through the reduction of.
Dexmedetomidine vs Midazolam for Sedation of Critically Ill Patients A Randomized Trial Journal Club 09/01/11 JAMA, February 4, 2009—Vol 301, No
SEDATIVES/HYPNOTICS BY KIMBERLY ROEMER. HISTORY OF SEDATIVES Sedatives have been around since the 1800’s. Potassium Bromide was used in 1830 as a sedative.
Role of Medications in Recovery and the Prevention of Relapse Mark Publicker, MD FASAM Medical Director, Mercy Recovery Center, Westbrook Maine.
Valproic Acid to Treat Agitation in Dementia By: Samia B.
Stapleford-Athens 2011 International Addiction Conference Developing a rehab program with NTX as one entry requirement Dr George O’Neil
Drug Detoxification revisited Dr Lucy Cockayne Consultant Psychiatrist NHS Lanarkshire.
How and Why Drugs Work Chapter 5
Stapleford-Athens 2011 International Addiction Conference Naltrexone Implants for the Treatment of Alcohol Dependence Dr George O’Neil
Biology of Substance Abuse
CIWA Protocol: Fraser Health
An Educational Perspective Based on Information Contained In The Indiana Prevention Resource Center Factline on Benzodiazepines ®
 BNZ-1 r.: sedation, hypnotic, antianxiety  BNZ-2 r.: anxiolysis, muscle relaxation, sedation, anticonvulsant, psychomotor impairment  BNZ-3 r.: tolerance,
CASE VIGNETTE: Layla is 31 year old female. She came to your clinic complaining of fearfulness, palpitations, shortness of breath and impaired concentration.
BUPRENORPHINE TREATMENT: A TRAINING FOR MULTIDISCIPLINARY ADDICTION PROFESSIONALS Module III – Buprenorphine 101.
PHARMACOLOGY CNS 2 ANXIOLYTICS, HYPNOTICS AND SEDATIVES
Medication Assisted Therapy for Opioid Addiction: Methadone and Buprenorphine Andrew J. Saxon, M.D. Veterans Affairs Puget Sound Health Care System and.
Lynda Sharrett-Field Addiction Therapy-2014 Chicago, USA August 4 - 6, 2014.
Good Prescribing to support Criminal Justice Interventions
Chapter 10 - Sedatives.  Sedative-Hypnotics: calm us down and produce sleep  Antianxiety Drugs: tranquelizers.
1 Sedative-Hypnotics Benzodiazepines Megan Trimble Doctor of Pharmacy Candidate April 2006.
Barbiturates and Benzodiazepines Prescription Medication Drugs.
Ehab Sayed Ramadan Addiction Therapy 2015 Florida, USA August 03-08, 2015.
1 Benzodiazepines and Similar Drugs: Misuse, Abuse, and Dependence Randy Brown, MD University of Wisconsin, Madison Alcohol Medical Scholars Program Copyright.
Mechanism of action It interacts with specific receptors in the CNS, particularly in the cerebral cortex. Benzodiazepine-receptor binding enhances the.
Pharmacologic Considerations in the Treatment of Anxiety Disorders Presented by: Ann M. Hamer, PharmD, BCPP Date: 1/15/2015.
Sedative-Hypnotic Drugs
B ENZODIAZEPINE DEPENDENCE. WHO - ICD 10 C RITERIA FOR S UBSTANCE D EPENDENCE A definite diagnosis of dependence syndrome should usually be made only.
OCD, PTSD, and Panic Disorders. OCD Biological basis remains unknown But there seems to be some genetic component related to OCD and other anxiety disorders.
DRUGS OF ABUSE Reynaldo J. Lesaca, M.D. Reynaldo J. Lesaca, M.D.
Drugs used in treatment of addiction
Substance Misuse Dr. Graham Roberts. Content  Benzodiazepine management  Alcohol screening and brief intervention.  Substance misuse update.  Benzodiazepine.
The COMBINE Study: Design and Methodology Stephanie S. O’Malley, Ph.D. for The COMBINE Study Research Group JAMA Vol. 295, , 2006 (May 3 rd.
Drug addiction – learning gone wild? Dr Stuart McLaren MRCPsych. Phase 1 Psychopharmacology module
Psychopharmacology psychopharmacology – study of drugs and behavior
Peter Coleman MD The Coleman Institute Richmond Va. USA.
Reminder: What Information Will be Covered for EVERY Drug: What is drug? Why is it used? How is it administered? How much is used? Metabolism? Affects.
Clinical Management Course: Medical Complications of Alcoholism Peter R. Martin, M.D. Professor of Psychiatry and Pharmacology.
Weaning off BENZODIAZEPINES After Long-Term Use By Dr Sadaf Cheema GPST2.
Buprenorphine {Suboxone®, Subutex®}
UCLA Brain Institute Outreach Adrina Kocharian and Rachel Oseas.
Samantha Mohammad And Jack Utz
1 Varenicline for smoking cessation Robert West University College London Logroño, October
Vivitrol (Naltrexone) Treatment for opioid addiction.
Targeted medication 은 가능한가 ? 알코올 사용장애 환자의 치료 전략으로 건양대학병원 정신과 기 선 완.
Managing Alcohol and Opioid Withdrawals
Medications for the Treatment of Opioid Addiction Robert P. Schwartz, M.D. Friends Research Institute.
December 10, 2015 Arthur Robin Williams MD MBE American Academy of Addiction Psychiatry Division on Substance Abuse Department of Psychiatry, Columbia.
Medication Assisted Treatment Daniel T. Brown, D.O. Medical Director, Meridian HealthCare.
MHD & Therapeutics is proud to present And Now Here Is The Host... Insert Name Here.
Gregory S. Brigham, Ph.D., CEO
Drugs used for anxiety and panic disorders
Reset your Stressed Life in Healthy Life with Librium Medication
Chapter 38 Drug Abuse II: Alcohol 1.
Clinical Pharmacokinetics
Insomnia pharmacotherapy: Off-label antipsychotics
CNS Depressants: Sedative-Hypnotics Chapter 6
Pharmacologic Interventions for Unhealthy Drinking
School of Pharmacy, University of Nizwa
Presentation transcript:

Stapleford-Athens 2011 International Addiction Conference Further Experience with Ambulatory Benzodiazepine detox Dr George O’Neil Fresh Start Recovery Programme Perth, Western Australia

History of Flumazenil treatment for benzodiazepine addiction 1961: Hollister, L.E., Motzenbecker, F.P. & Degan, R.O. (1961) Withdrawal reactions from chlordiazepoxide ('Librium'). Psychopharmacologia, 2, : McNicholas, L.F. & Martin (1982) The effect of a benzodiazepine antagonist, R , in diazepam dependent rats. Life Science. Vol 31, (8); : Savic, I., Widen, L, & Stone-Elander, S. (1991) Feasibility of reversing benzodiazepine tolerance with flumazenil. Lancet 337: : Lader, M.H. & Morton S.V. (1992) A pilot study of the effects of flumazenil on symptoms persisting after benzodiazepine withdrawal. Journal of Psycopharmacology 6(3);

History - continued 1996: Gerra, G. et al (1996) Intravenous flumazenil following prolonged exposure to lormetazepam in humans: lack of precipitated withdrawal. International Clinical Psychopharmacology, Jun;11(2):81-8 –IV flumazenil following prolonged exposure to lormetazepam 2002: Gerra, G. Zaimovic, A., Giusti, F., Moi, G. & Brewer, C (2002) Intravenous flumazenil versus oxazepam tapering in the treatment of benzodiazepine withdrawal: a randomized, placebo-controled study. Addiction Biology, 7(4): patients 20 flumazenil. 20 oxazepam taper; 10 placebo -Demonstrated flumazenil efficiency at reversing benzo effects and withdrawal symptoms. 2004: Pericic, D. et al (2004) Chronic exposure of cells expressing recombinant GABB A receptors to benzodiazepine antagonist flumazenil enhances the maximum number of benzodiazepine binding sites. Life Science, Vol 76 (3): –Prolonged occupancy of benzo receptors by benzos leads to uncoupling of the allosteric linkages to the GABBA receptor. –Result - Tolerance/ craving for benzos, Flumazenil – recouples receptor function –Resets tone. Tolerance & cravings decrease.

Background Gerra et al (2002) demonstrated that flumazenil was efficient at reversing the effects of benzodiazepine and withdrawal symptoms. In 2006, we reported IV flumazenil infusions in 29 benzodiazepine dependent patients

Experience with flumazenil infusions Melbourne – IV only – (SC only) –4 day (In Patient only) Perth – IV only (usually 4 days) – SC only (4-30 days) –out patient with carer after first 2 days.

Flumazenil 12mg/30ml filtered infusion system

Jon Currie, Melbourne Blood Levels

Perth Flumazenil Work Continuous infusion of µg/hr causes some detox symptoms in the first 6hrs with relief of anxiety and aggression during the infusion. Subcutaneous infusion have proven more reliable in more than 100 patients compared to 100 managed by IV infusion Patients were noted to have a return of anxiety when the infusion stoped and so the infusion is now continued up to 30 days

Flumazenil reducing cravings for Benzodiazepines Hood, S., O’Neil, G & Hulse, G. (2009) The role of flumazenil in the treatment of benzodiazepine dependence: physiological and psychological profiles. Journal of Psychopharmacology, 23(4);

Perth Flumazenil Work cont. Perth is the first city to allow the patients home providing a carer remains with them after the first 1-2 days of infusion. Research work is continuing; –Flumazenil implants –Flumazenil injections 7-28 days –Flumazenil patches

Prolonged infusions Detox symptoms in first 6 hours usually. Detox symptoms usually settle but in high benzo users can continue for days. Anxiety may return when infusion stops but the return of anxiety is decreased with long infusions. Anxiety control, cognitive depression and depression symptoms all improve with length of the infusion.

In Vitro Release of FLU/PLA/PLGA tablets

Perth Flumazenil Infusions Aug IV infusions balloon driven –Patients became irritable whenever the infusion was stop by a blocked IV site –On one occasion a patient fitted 100+ Subcutaneous infusions –No obstructions to flow occurred and outpatient management became practical

Drug use Before & After Naltrexone & Flumazenil (Hood, 2009)

Flumazenil Reducing Anxiety (Hood, 2009)

Flumazenil infusions the future Subcutaneous has replaced IV Nasal may be useful for symptom control. Transdermal experiments are continuing. Implant delivery; trial protocols are developed. Use in benzo addiction is well demonstrated. Use in alcohol, amphetamine and other addictions is less well established.

Karolinska Institute 2010 In aggressive patients flumazenil decreases the existing aggression In the control group, flumazenil increases aggression and alertness The dose delivery method of large bolus intermittent doses may have caused aggression in the controls where it is my belief that a continuous low dose infusion might have increased alertness without increasing aggression. Saxon, L., Borg, S. & Hiltunen, A.J. (2010) Reduction of aggression during benzodiazepine withdrawal: Effects of flumazenil. Pharmacology, Biochemistry and Behaviour, 96,

Croatia 2008, Molecular & Neuropharmacology They confirm up-regulation of GABA A receptors may be from; –Growth of new receptors via synthesis of receptor proteins confirmed with their experiments during prolonged flumazenil exposure or –Via flumazenil causing the correction of uncoupling of non sensitive GABA A receptors so that they return to full sensitivity (uncoupling of receptors follows exposure to benzodiazepines) Jazvinscak, M. et al (2008) The role of transcriptional and translational mechanisms in flumazenil-induced up-regulation of recombinant GABA A receptors. Neuroscience Research, 61;

GABA A Receptor

Case Study – Female Aged 30 Childhood terror PTSD diagnosed at 15 Anxiety led to 20 years benzo and 10 years opiate addiction Total of 35 admissions for benzo overdoses requiring ventilation occurred

Case Study – Female Aged 30 cont. Presenting medications: –200 x 2mg/day Xanax (alprazolam) –50 x 5mg/day Valium (diazepam) –50 x 5mg/day Mogadon (nitrazepam) –1600 mg/day Seroquel (quetiapine: atypical antipsychotic) –80/day Panadeine Forte (co-codamol: each tablet paracetamol 500 mg + codeine phosphate 30 mg) Naltrexone implants to control the opiate disorder Flumazenil infusions to control the GABA A system anxiety disorder

Heart rate patterns following Valium at midday and flumazenil at 6.15pm Heart rate (bpm) Valium (agonist)Flumazenil (antagonist)

Case Study – female aged 50 PTSD following presence at 9/11 Stilnox addiction (agonist at benzo receptor) followed sleep disturbance Culminating in 20 tab/day Stilnox (zolpidem) Treated with flumazenil infusions to upregulate (re-sensitise) the benzo receptors damaged by chronic stress from PTSD and Stilnox

Contact Information Dr George O’Neil Phone –Perth (GMT+8) 6-8am or 7-11pm –London (GMT) 10-12pm or 11am-3pm –New York (GMT-5) 5-7pm or 6-10am –Los Angeles (GMT-8) 2-4pm